landmark trials Flashcards

1
Q

What is the primary research question of the TRUFFLE study?

A

Assess whether changes in fetal ductus venosus (DV) doppler waveform changes could be used instead of short-term variation (STV) to trigger delivery in pregnancies with diagnosis of fetal growth restriction.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What was the study design of the TRUFFLE trial?

A

Prospective, multicentre, unblinded, randomised trial.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What were the inclusion criteria for the TRUFFLE study?

A
  • Singleton pregnancies
  • 26-32 weeks of gestation
  • Diagnosis of fetal growth restriction (FGR)
  • AC < 10th centile
  • High umbilical artery doppler PI > 95th centile regardless of EDF pattern.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What were the exclusion criteria for the TRUFFLE study?

A
  • EFW <500g at inclusion
  • Abnormal DV A wave or PI at inclusion
  • Decreased STV at inclusion
  • Fetal structural or karyotype abnormality.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What were the primary and secondary outcomes of the TRUFFLE study?

A

Primary: survival without neurodevelopmental impairment at 2 years. Secondary: median age of delivery, mean birth weight.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What conclusion was drawn from the TRUFFLE study regarding delivery timing?

A

The study supports waiting for late DV changes for delivery <32 weeks.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What was the main finding of the CLASP trial regarding low-dose aspirin?

A

Low-dose aspirin may be justified in women at high risk of early-onset pre-eclampsia.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What was the primary outcome measured in the CLASP trial?

A

Development of proteinuric pre-eclampsia (PET).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What was the result of the ACTORDS trial concerning repeat prenatal corticosteroids?

A

Fewer babies exposed to repeat corticosteroids had respiratory distress syndrome.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What was the intervention used in the ACTORDS study?

A

Repeat IM betamethasone 11.4mg, administered weekly until 32 weeks gestation or until delivery.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What was the primary outcome of the study on prophylactic administration of progesterone?

A

Preterm delivery before 37 weeks.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What significant result was found regarding preterm delivery rates in the progesterone study?

A

Reduced rates of preterm delivery in the progesterone group (13.8%) compared to placebo (28.5%).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What was the primary research question of the ACHOIS study?

A

Effect of treatment of gestational diabetes mellitus on pregnancy outcomes.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What were the inclusion criteria for the ACHOIS study?

A
  • Singleton or twin pregnancy between 16 to 30 weeks
  • Attended antenatal clinics at collaborating hospital.
  • One or more risk factors for GDM on selective screening.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What was the intervention used in the ACHOIS study?

A

Individualised dietary advice, blood glucose monitoring, and insulin therapy.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What was the outcome measured regarding neonatal complications in the ACHOIS study?

A

Composite serious perinatal complications including death, shoulder dystocia, and nerve palsy.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What was a key limitation noted in the TRUFFLE study?

A

Limited to tertiary centres with specialist MFM able to undertake arterial and venous doppler assessments regularly.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

True or False: In the CLASP trial, there was a statistically significant reduction in the development of proteinuric PET with aspirin.

A

False.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Fill in the blank: The ACTORDS trial found that repeat prenatal corticosteroids reduced the incidence of _______.

A

[neonatal respiratory distress syndrome].

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What was the mean birth weight reported in the primary outcomes of the TRUFFLE study?

A

1019g.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What was a noted criticism of the ACHOIS study regarding its population?

A

Women with more severe glucose impairment were excluded.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What are composite serious perinatal complications?

A

Death, shoulder dystocia, bone fracture, and nerve palsy

These complications are assessed using a standardized checklist during birth.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What was the primary outcome comparing the intervention group to the routine-care group?

A

Lower rates of serious perinatal outcomes (1% vs 4%; P=0.01, NNT 34)

NNT stands for Number Needed to Treat.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

What was the percentage of neonatal nursery admission for the intervention group compared to the routine-care group?

A

61% in the intervention group vs 71% in the routine-care group (adjusted P=0.01)

Indicates a significant difference in nursery admission rates.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Was there a significant difference in jaundice requiring phototherapy between the two groups?

A

No significant difference (P = 0.72)

This suggests similar rates of jaundice in both groups.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

What was the increase in induction of labour rates in the intervention group?

A

39% in the intervention group vs 29% in the routine-care group (P< 0.001)

This indicates a significant increase in induction rates.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

What were the perinatal death rates in the intervention group compared to the routine care group?

A

No perinatal deaths in the intervention group; 5 in the routine care group (3 stillbirths and 2 neonatal deaths)

Highlights the safety of the intervention.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

What was the impact of the intervention on birth weights?

A

Lower mean birth weights in the intervention group compared to the routine-care group (P<0.001)

This is associated with earlier deliveries due to higher induction rates.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

What percentage of women received insulin in the intervention group?

A

20% (100 women) in the intervention group vs 3% (17 women) in the routine care group

Reflects the management of gestational diabetes in the study.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

What was the conclusion regarding the treatment of GDM?

A

Dietary advice, blood glucose monitoring, and insulin therapy reduce serious perinatal complications without increasing CS rates

Emphasizes effective management strategies for gestational diabetes.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

What was a notable criticism of the study design?

A

Women were not informed of their diagnosis of gestational diabetes during the study

Raises ethical concerns regarding informed consent.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

What is the role of magnesium sulphate in preterm birth?

A

Used as a neuroprotective agent for fetuses at risk of preterm birth

Aimed at preventing neurological impairments in newborns.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

What were the primary outcomes of magnesium sulphate treatment?

A

No difference in paediatric mortality; reduced risk of cerebral palsy and gross motor dysfunction

Highlights the benefits of magnesium sulphate for neurological outcomes.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

What was the NNT to benefit one baby from magnesium sulphate treatment?

A

63 (95% confidence interval 43 to 155)

Indicates the number of women needed to treat to prevent one case of cerebral palsy.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

What were the inclusion criteria for the MAGPIE trial?

A

Women with preeclampsia not yet given birth or <24h postpartum with specific blood pressure and proteinuria criteria

Ensures that the study population met necessary health conditions.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

What was the primary outcome of the MAGPIE trial?

A

Eclampsia prevention and neonatal death before discharge

Focused on maternal and neonatal health outcomes.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

What is the effect of progesterone on preterm birth risk?

A

Reduces rates of spontaneous delivery <34 weeks

Proven effective for women with a short cervix.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

What was the primary outcome of the ARRIVE trial?

A

Lower risk of composite outcome of perinatal death or severe neonatal complications with elective induction at 39 weeks

Indicates potential benefits of early induction in low-risk pregnancies.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

What was the sample size of participants in the ARRIVE trial?

A

6106 participants (3062 intervention, 3044 comparator)

Reflects the scale of the trial.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

What is singleton gestation?

A

A single fetus developing during pregnancy.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

What is the eligibility criterion for twin gestation reduced to singleton?

A

Reduction must occur before 14 weeks 0 days project gestational age.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

What is the gestational age range for randomization in the study?

A

Between 38 weeks 0 days and 38 weeks 6 days inclusive.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

What type of presentation is required for eligibility?

A

Vertex presentation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

What is an exclusion criterion related to ultrasound timing?

A

Project gestational age at date of first ultrasound is > 20 weeks 6 days.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

What is the maximum gestational age for induction of labour in this study?

A

Prior to 40 weeks 5 days.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
46
Q

Name a maternal medical condition that excludes participation.

A

Any diabetes mellitus.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
47
Q

What is the primary outcome of the study?

A

Composite of perinatal death or severe neonatal complications.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
48
Q

List two severe neonatal complications included in the primary outcome.

A
  • Need for respiratory support within 72 hours after birth
  • Hypoxic–ischemic encephalopathy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
49
Q

How is fetal growth restriction defined in this study?

A

EFW < 10th percentile.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
50
Q

What was the result regarding the primary composite perinatal outcome?

A

No statistically significant difference in the induction group.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
51
Q

What was the reduction in caesarean delivery in the induction group?

A

Decreased from 22.2% to 18.6%; RR, 0.84.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
52
Q

What is a criticism regarding the primary outcome’s statistical significance?

A

Not statistically significant.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
53
Q

What intervention was studied for women at risk for late pre-term delivery?

A

Antenatal betamethasone.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
54
Q

What was the primary neonatal outcome measured in the betamethasone study?

A

Neonatal composite outcome for respiratory support by 72 hours.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
55
Q

What was the result of betamethasone administration on neonatal outcomes?

A

Decreased need for substantial respiratory support.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
56
Q

What increased risk was noted in the betamethasone group?

A

Increased risk of neonatal hypoglycaemia.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
57
Q

What type of trial was the Term Breech Trial?

A

International multicentre randomised control trial.

58
Q

What was the primary outcome of the Term Breech Trial?

A

Perinatal or neonatal mortality at <28 days of age.

59
Q

What was the conclusion regarding planned caesarean section versus vaginal birth?

A

Planned caesarean section is better than planned vaginal birth for term breech presentation.

60
Q

What is the significance of the NNT in the Term Breech Trial results?

A

NNT 14 for significantly lower risk of perinatal/neonatal morbidity.

61
Q

What was a major criticism of the Term Breech Trial?

A

Standard of care was not consistent.

62
Q

What was the research question of the TERMPROM study?

A

Is IOL in women with PROM at term preferable to waiting for spontaneous labour?

63
Q

What does PROM stand for?

A

Prelabour rupture of membranes.

64
Q

What was the study design for the TERMPROM trial?

A

International multicentre randomised control trial.

65
Q

What is the research question of the study conducted by Hannah et al?

A

Is IOL in women with PROM at term preferable to waiting for spontaneous labour if there is no evidence of fetal or maternal compromise.

66
Q

What was the study design of the trial conducted by Hannah et al?

A

International, multicentre randomised control trial.

67
Q

What were the inclusion criteria for the study by Hannah et al?

A
  • ROM > 37 weeks
  • Singleton
  • Cephalic
68
Q

What were the exclusion criteria for the study by Hannah et al?

A
  • Active labour
  • Previous failed IOL
  • Contraindication to IOL
  • Meconium-stained liquor
  • Chorioamnionitis
69
Q

What was the intervention in the study by Hannah et al?

A

Immediate IOL with subgroups IV oxytocin or PV prostaglandin.

70
Q

What was the comparator in the study by Hannah et al?

A

Expectant management for up to 4 days.

71
Q

What were the primary outcomes measured in the study by Hannah et al?

A

Definite or probable neonatal infection.

72
Q

How was definite neonatal infection defined in the study by Hannah et al?

A

Presence of clinical signs of infection and > 1 of the following: positive blood culture, CSF, urine, tracheal aspirate or lung tissue, positive gram stain of CSF, CXR compatible with pneumonia or histologic dx of pneumonia.

73
Q

What was the conclusion of the study by Hannah et al?

A

For term PROM, IOL with oxytocin or prostaglandin E2 and expectant management result in similar rates of neonatal infection and caesarean section.

74
Q

What was the main criticism of the study by Hannah et al?

A

Women with GBS were not managed differently from those without GBS.

75
Q

What is the research question of the ORACLE I study?

A

Does initiating antibiotics in PPROM have benefits for the neonate?

76
Q

What was the primary outcome measured in the ORACLE I study?

A

Composite of neonatal death, chronic lung disease, major cerebral abnormality on USS before discharge from hospital.

77
Q

What were the secondary outcomes of the ORACLE I study?

A
  • Delivery <48hrs or 7 days
  • Mode of delivery
  • Gestation at birth
  • BW <2500g or <1500g
  • Admission to NICU
  • Requirement for ventilation, RDS
  • Positive blood cultures
  • NEC
78
Q

What were the results regarding erythromycin in the ORACLE I study?

A

Erythromycin alone was associated with decreased primary outcomes vs placebo.

79
Q

What was the conclusion of the ORACLE I study?

A

In singleton pregnancies, erythromycin decreases neonatal death, chronic lung disease, and major cerebral abnormality on USS.

80
Q

What was the research question of the 7-year follow-up of the ORACLE I trial?

A

Does initiating antibiotics in preterm labour with intact membranes have benefits for the neonate?

81
Q

What were the primary outcomes measured in the 7-year follow-up of the ORACLE I trial?

A

Presence of any level of functional impairment from mark III MAHS system.

82
Q

What was the conclusion of the 7-year follow-up of the ORACLE I trial?

A

The prescription of antibiotics for women with preterm rupture of the membranes seems to have little effect on the health of children at 7 years of age.

83
Q

What is the research question of the ORACLE II study?

A

Does initiating antibiotics in preterm labour with intact membranes have benefits for the neonate?

84
Q

What were the results regarding the use of antibiotics in the ORACLE II study?

A

No evidence that use of any antibiotic regimen prolonged pregnancy or influenced mode of delivery.

85
Q

What was the conclusion of the ORACLE II study?

A

Antibiotics should not be routinely prescribed to women in spontaneous preterm labour without clinical evidence of infection or PPROM.

86
Q

What is the research question of the 7-year follow-up of the ORACLE II trial?

A

Does initiating antibiotics in preterm labour with intact membranes have benefits for the neonate?

87
Q

What were the primary outcomes measured in the 7-year follow-up of the ORACLE II trial?

A

Presence of any level of functional impairment from mark III MAHS system.

88
Q

What was the conclusion of the 7-year follow-up of the ORACLE II trial?

A

Erythromycin for women in spontaneous preterm labour with intact membranes was associated with an increase in functional impairment among their children at 7 years of age.

89
Q

What is the research question of the HYPITAT study?

A

To compare the outcomes of induction of labour and expectant monitoring in pregnant women with gestational hypertension or mild preeclampsia between 36- and 41-weeks’ gestation.

90
Q

What was the study design of the HYPITAT study?

A

Multicentre, parallel, open label randomised controlled trial.

91
Q

What was the number of patients involved in the HYPITAT study?

A

756 women.

92
Q

What were the inclusion criteria for the HYPITAT study?

A

Women with gestational hypertension or mild preeclampsia between 36- and 41-weeks’ gestation.

93
Q

What was the primary research question of the study on induction of labour and expectant monitoring?

A

To compare the outcomes of induction of labour and expectant monitoring in pregnant women with gestational hypertension or mild preeclampsia between 36- and 41-weeks’ gestation.

94
Q

What type of study design was used in the trial comparing induction of labour and expectant monitoring?

A

Multicentre, parallel, open label randomised controlled trial.

95
Q

During which years was the study on induction of labour conducted?

A

2005 - 2008.

96
Q

How many patients were involved in the trial comparing induction of labour and expectant monitoring?

A

756 patients.

97
Q

What were the inclusion criteria for the study on induction of labour?

A
  • Singleton pregnancy
  • Cephalic presentation
  • Gestational age of between 36 and 41 weeks at enrolment
  • Gestational hypertension or mild pre-eclampsia.
98
Q

How was gestational hypertension defined in the study?

A

Diastolic blood pressure of 95mm Hg or higher measured on two occasions at least 6 hours apart.

99
Q

What is mild pre-eclampsia defined as in the study?

A

Diastolic blood pressure of 90 mm Hg or higher measured on two occasions at least 6 hours apart, combined with proteinuria.

100
Q

What were the exclusion criteria for the study on induction of labour?

A
  • Severe gestational hypertension or pre-eclampsia
  • Use of IV hypertensives or pre-existing hypertension
  • HELLP syndrome
  • Oliguria of less than 500 mL per 24 h
  • Medical conditions such as pre-existing diabetes requiring insulin
  • Previous caesarean section
  • Fetal anomalies.
101
Q

What was the primary outcome of the study comparing induction of labour and expectant monitoring?

A

Composite of maternal mortality, maternal morbidity, progression to severe hypertension or proteinuria, and major postpartum hemorrhage.

102
Q

What was the result regarding maternal outcomes in the induction of labour group?

A

Decreased poor maternal outcome (31% vs 44% RR risk 0·71, 95% CI 0·59–0·86, p<0·0001).

103
Q

What conclusion was drawn from the study on induction of labour for women with mild hypertensive disease?

A

Induction of labour is associated with improved maternal outcome and should be advised for women with mild hypertensive disease beyond 37 weeks’ gestation.

104
Q

What was the primary question of the PPROMT trial?

A

Does a policy of inducing labour reduce neonatal infection without increasing other morbidity?

105
Q

What was the study design of the PPROMT trial?

A

Randomised controlled trial using a central telephone service.

106
Q

How many patients were included in the PPROMT trial?

A

1839 patients.

107
Q

What were the inclusion criteria for the PPROMT trial?

A
  • Ruptured membranes prior to the onset of labour between 34+0 and 36+6 weeks
  • No clinical signs of infection.
108
Q

What were the primary outcomes of the PPROMT trial?

A

Definite or probable neonatal infection.

109
Q

What was concluded from the PPROMT trial regarding management of PPROM?

A

In the absence of overt signs of infection or fetal compromise, expectant management with appropriate surveillance should be followed.

110
Q

What was the main research question in the WOMAN trial?

A

Does early administration of tranexamic acid affect death, hysterectomy, and other morbidities in women with postpartum hemorrhage?

111
Q

What study design was used in the WOMAN trial?

A

International, multicentre, randomised double-blind, placebo-controlled trial.

112
Q

What was the primary outcome measured in the WOMAN trial?

A

Composite outcome: death from all causes or hysterectomy within 42 days of randomisation.

113
Q

What was the result regarding the risk of death due to bleeding in the WOMAN trial?

A

Risk of death due to bleeding was significantly reduced in patients that received TXA within 3 hours of PPH.

114
Q

What conclusion was made regarding tranexamic acid in the WOMAN trial?

A

Tranexamic acid reduces death due to bleeding with no adverse effects.

115
Q

What was the research question of the antenatal betamethasone study?

A

Do steroids reduce respiratory distress in babies born by elective caesarean section at term?

116
Q

What was the primary outcome of the antenatal betamethasone study?

A

Admission to special care baby unit with respiratory distress.

117
Q

What was concluded regarding antenatal betamethasone in the study?

A

Antenatal betamethasone reduces admissions to special care baby units with respiratory distress after elective caesarean section.

118
Q

What was the primary research question of the twin pregnancy delivery study?

A

Whether planned caesarean section results in a lower risk of adverse outcomes than planned vaginal delivery in twin pregnancy.

119
Q

What were the inclusion criteria for the twin pregnancy delivery study?

A
  • Twin pregnancy
  • Between 32 weeks 0 days and 38 weeks 6 days of gestation
  • First twin in cephalic presentation.
120
Q

What was the primary outcome of the twin pregnancy delivery study?

A

A composite of fetal or neonatal mortality or serious neonatal morbidity.

121
Q

What was the result of the twin pregnancy delivery study regarding the planned delivery methods?

A

No significant difference in the composite primary outcome between planned caesarean and vaginal delivery.

122
Q

What is the primary outcome measured in the study regarding planned caesarean delivery versus planned vaginal delivery?

A

Composite of mortality or serious neonatal morbidity

Includes birth trauma of infant, intracerebral haemorrhage or IVH, APGAR <4 at 5min, intubation, confirmed septicemia, NEC.

123
Q

What were the primary outcome percentages for the planned-caesarean-delivery group and the planned-vaginal-delivery group?

A

2.2% for planned caesarean delivery and 1.9% for planned vaginal delivery

OR, 1.16; 95% confidence interval, 0.77 to 1.74; P=0.49.

124
Q

What was the secondary outcome measured for maternal health in the study?

A

Composite of maternal death or serious maternal morbidity before 28 days

Includes death, PPH >1.5L, blood transfusion, laparotomy, damage to bladder/bowel/ureter, confirmed sepsis, wound infection requiring readmission or breakdown.

125
Q

What was the percentage of caesarean delivery in the planned-caesarean-delivery group?

126
Q

What was the percentage of caesarean delivery in the planned-vaginal-delivery group?

127
Q

What was the conclusion regarding the benefits of planned caesarean section compared to planned vaginal delivery for twins?

A

No benefits of planned caesarean section if the first twin was in cephalic presentation.

128
Q

What limitation was noted regarding subgroup analysis in the study?

A

Not powered for subgroup analysis, particularly MCDA twins.

129
Q

What was the research question of the HAPO study?

A

Is maternal hyperglycaemia less severe than in diabetes mellitus associated with increased risks of adverse pregnancy outcomes?

130
Q

What was the study design of the HAPO study?

A

Multicentre, blinded observational study.

131
Q

How many patients participated in the HAPO study?

A

28,562 agreed to participate.

132
Q

What were the inclusion criteria for the HAPO study?

A

Singleton pregnancy, age >18 years with certain gestational age.

133
Q

What was the primary outcome of the HAPO study?

A

Birth weight >90%, primary caesarean delivery, clinical neonatal hypoglycaemia, cord-blood serum C peptide level >90%.

134
Q

What were some secondary outcomes measured in the HAPO study?

A

Premature delivery, shoulder dystocia, birth injury, need for NICU, hyper-bilirubinaemia, pre-eclampsia.

135
Q

What were the findings regarding associations with birth weight >90% in the HAPO study?

A

Strong associations that increased across increasing glycaemia categories.

136
Q

What decision was made based on the results of the HAPO study regarding GDM diagnostic criteria?

A

To alter the diagnostic criteria of GDM based on RR of 1.75.

137
Q

What confounders were noted as potential influences on outcomes in the HAPO study?

A

Previous GDM, maternal BMI, previous macrosomia.

138
Q

True or False: The observational design of the HAPO study can conclusively establish that maternal glycaemia is causally related to adverse outcomes.

139
Q

What was the rate of blinding in the HAPO study?

140
Q

What challenge was noted regarding the translation of HAPO study findings into clinical practice?

A

Lack of clear thresholds for risk and unequal clinical importance of primary outcomes.